
|Articles|December 1, 2004
Miravant selects new name for SnET2
Santa Barbara, CA-Miravant Medical Technologies has picked Photrex as the brand name for its tin ethyl etiopurpurin (SnET2) drug being developed for photodynamic therapy in the treatment of wet AMD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Beyond the surface: Tackling complex dry eye cases
2
Seborrheic dermatitis linked to multiple epithelial barrier diseases
3
Q&A: Anat Loewenstein discusses the use of home OCT
4
Redefining glaucoma care: Where innovation meets clinical insight
5


















































.png)


